Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies.

ABSTRACT: With the continuous improvement in survival of cancer patients, including those with multiple myeloma, related to the novel treatment agents and therapeutic approaches, the probability for patients to develop cardiovascular disease has significantly increased, especially in elderly patients and those with additional risk factors. Multiple myeloma is indeed a disease of the elderly population and so these patients are, solely by age, at an increased risk of cardiovascular disease. Risk factors for these events can be patient-, disease- and/or therapy-related, and they have been shown to adversely impact survival. Cardiovascular events affect around 7.5% of patients with multiple myeloma and the risk for different toxicities has considerably varied across trials depending on patients' charac

SUBMITTER: El-Cheikh J 

PROVIDER: S-EPMC10199017 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature